Objectives: Although most susceptibility studies for linezolid have investigated aerobic bacteria, only a few have investigated anaerobe isolates. The aim of the present study was to determine the antibacterial activity of linezolid against a larger sample of clinical isolates of Fusobacterium spp. and to report on the detailed susceptibility, stratified by species.
Introduction
Linezolid is an oxazolidinone-class antibacterial agent which inhibits bacterial protein synthesis by specifically binding to the 50S ribosomal subunit. Although other antibacterial agents including chloramphenicol, fusidic acid, lincosamides, macrolides, streptogramins and tetracyclines act by inhibiting protein synthesis, linezolid's specific binding to the 50S ribosomal subunit makes quick cross-resistance with existing antibacterial compounds unlikely. [1] [2] [3] [4] Linezolid is not active (MIC > 64.0 mg/L) against Pseudomonas spp., Acinetobacter spp. or Enterobacteriaceae, including Escherichia coli, Klebsiella pneumoniae and Proteus penneri.
However, linezolid has good in vitro activity against a wide variety of Gram-positive aerobic bacteria, in particular against methicillin-resistant staphylococci, including methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae and vancomycin-resistant enterococci (VRE), including Enterococcus faecalis and Enterococcus faecium. In addition, it shows activity against Nocardia spp. and good activity against Streptococcus pyogenes, Bacillus spp., Corynebacterium spp., Listeria monocytogenes, Mycobacterium tuberculosis and Rhodococcus spp. 5, 6 Linezolid is less active against Gram-negative aerobic bacteria and lacks significant in vitro effects against most Gramnegative pathogens but shows moderate in vitro activity (MIC 4.0-8.0 mg/L) against Moraxella catarrhalis, Haemophilus influenzae, Legionella spp. and Bordetella pertussis or Bordetella parapertussis. Linezolid also exhibits MICs of 2.0 and 4.0 mg/L against Flavobacterium meningosepticum and Pasteurella multocida, respectively. Although most susceptibility studies for linezolid have investigated aerobic bacteria, only a few have investigated anaerobe isolates. For fusobacteria, there are even fewer published reports. [7] [8] [9] [10] [11] [12] [13] [14] So far, the susceptibility of only a total of 129 fusobacteria has been published in eight papers, with the most frequent species being Fusobacterium nucleatum (33%, n = 42). With one exception, linezolid was effective against all strains of fusobacteria with MIC 90 values ranging from 1.0 to 2.0 mg/L.
The aim of the present study was to determine the antibacterial activity of linezolid against a larger sample of clinical isolates of Fusobacterium spp. and to report on the detailed susceptibility, stratified by species.
Materials and methods
A total of 80 clinical isolates of Fusobacterium spp. were investigated (Fusobacterium necrophorum, n = 34; F. nucleatum, n = 20; Fusobacterium varium, n = 18; Fusobacterium mortiferum, n = 8). All isolates were obtained from patients with clinical infections caused by Fusobacterium and cultured at the Institute for Medical Microbiology, Martin-Luther-University Halle-Wittenberg, Halle/ Saale. All strains were identified by standard criteria. [15] [16] [17] [18] Three American Type Culture Collection (ATCC) strains (Bacteroides fragilis ATCC 25285, Bacteroides thetaiotaomicron ATCC 29741 and C. perfringens ATCC 13124) were included for quality control and assessment of reproducibility to each batch of test.
Pre-produced supplemented brucella-agar (Oxoid, Hampshire, UK) containing haemin, vitamin K1 and 5% laked sheep blood was used as test medium. An inoculum was stirred into 4 mL of sterile NaCl until an optical density equivalent to that of a 0.5 McFarland standard was reached. From this suspension, 50 mL was plated on brucella-agar. As controls, the same procedure was performed using reference strains Bacillus fragilis (ATCC 25285) and Bacteroides thetaiotaomicron (ATCC 29741).
MIC values were determined by Etest (AB Biodisk, Stockholm) according to the manufacturer's recommendations. All MIC results were recorded after 48 h of incubation at 35-36 C in an anaerobic environment. The MIC of a test antibiotic for an organism was defined as the lowest concentration of an antimicrobial agent yielding no growth.
Interpretation of linezolid susceptibility testing was performed by use of European Committee on Antimicrobial Susceptibility Testing (EUCAST) recommendations for non-species-related breakpoints (susceptible: 4.0 mg/L; resistant: >4.0 mg/L). For F. necrophorum, F. nucleatum and F. mortiferum, the MIC 50 s for amoxicillin and amoxicillin/clavulanic acid were lower than the MIC 50 s obtained for linezolid. However, for F. varium, the MIC 50 s for all three antibiotics were identical (0.5 mg/L).
For F. necrophorum and F. nucleatum, the MIC 90 s of linezolid were higher than the MIC 90 s of the two other antibiotics tested. For F. varium, the MIC 90 s of all three antibiotics were identical (0.75 mg/L), and again, the highest of all Fusobacterium species. The lowest MIC 90 against F. mortiferum was found for linezolid.
Compared with amoxicillin and amoxicillin/clavulanic acid, linezolid was less active against F. necrophorum and F. nucleatum, equally active against F .varium and slightly more active against F. mortiferum (Table 2) .
Discussion
In humans, predominant pathogenic anaerobes include Bacteroides spp., Peptostreptococcus spp., Gram-positive nonspore-forming bacilli, Clostridium spp. and Fusobacterium spp.
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Members of the Gram-negative anaerobic genus Fusobacterium are important in both the normal flora and infection. They are common inhabitants of the oral cavity, gastrointestinal tract and female genital tract. In dental plaque they may represent as much as 4% of all anaerobic isolates. 22 The most frequent isolates in human clinical infection are F. necrophorum, in liver abscesses, and F. nucleatum, in anaerobic pleuropulmonary infections including aspiration pneumonia, necrotizing pneumonia and lung abscess. 23 Both can cause chronic sinusitis, brain abscess, osteomyelitis, septic arthritis and intra-abdominal infections. However, neutropenic haematological patients exhibit a higher risk for F. nucleatum infections. 24 F. necrophorum is frequently found in patients with necrobacillosis (Lemierre's disease).
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F. mortiferum and F. varium are mainly isolated in patients with intra-abdominal infections. 25 Depending on the location of infection, the treatment of Fusobacterium infection entails surgical intervention and the use of appropriate antibiotics. Selection of appropriate antibiotics, however, is not a simple matter, since these infections are often polymicrobial. For many decades, penicillin G and cephalosporins were considered the drug of choice, with clindamycin and chloramphenicol as secondary alternatives. Later, however, a possible rise in the incidence of b-lactam antibiotic resistant strains was anticipated, which emphasized the need for alternative treatment options in the future. 27 Indeed, in 2001, Aldridge et al. 28 reported on 22 clinical Fusobacterium spp. isolates of which 2 were resistant to penicillin G and clindamycin, and recently it was reported that significantly higher MIC values were noted in Spanish strains of F. nucleatum for penicillin G and ciprofloxacin. 29 Although most antimicrobial agents are still active against Fusobacterium isolates, some authors express concern for what appears to be an increase in resistance to penicillin and clindamycin.
Only a few studies have been published on testing of antibacterial activity of linezolid against Fusobacterium.
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Within these studies (Table 3) , only a few isolates of Fusobacterium were tested, and, because of the low number of isolates, in most papers the Fusobacterium susceptibility was not stratified by species level. With one exception, 9 all studies showed 100% susceptibility to linezolid. Edlund et al. 9 14 investigated 6 Fusobacterium isolates. All reported 100% susceptibility to linezolid, although MIC ranges and MIC 90 s were consistently similar or higher than in our study (MIC 90 1.0-2.0 mg/L as compared with an MIC 90 of 0.75 mg/L in our study).
A study investigating susceptibility of F. necrophorum, F. nucleatum and F. varium was conducted by Yagi et al. 8 The susceptibility of all isolates to linezolid was 100%. However, four strains (F. necrophorum n = 2, F. nucleatum n = 1, F. varium, n = 1) were tested without indicating results by species level; overall, the MIC ranged higher (maximum MIC 4.0 mg/L) compared with the MIC ranges observed among 80 strains in our study (highest MIC: 1.0 mg/L). Yet, in both studies, the MIC 90 s were identical (0.5 mg/L).
In addition to 18 strains of F. nucleatum, Goldstein et al.
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tested 10 strains of different Fusobacterium species (F. necrophorum n = 1, Fusobacterium russii n = 6, Fusobacterium gonidiaformans n = 1, and Fusobacterium spp. n = 2) and found a higher MIC range (0.125-1.0 mg/L) but an identical MIC 90 (0.5 mg/L) of linezolid as in the present study.
In conclusion, with the exception of one study reporting on a linezolid-resistant organism of a non-defined species, 9 our study is in agreement with previously published susceptibility studies indicating 100% susceptibility of fusobacteria to linezolid. However, the present study shows lower MIC ranges and MIC 90 . In vitro, linezolid was effective against 80 clinical isolates of Fusobacterium: F. necrophorum (n = 34), F. nucleatum (n = 20), F. varium (n = 18) and F. mortiferum (n = 8). The MIC of linezolid against all isolates was below the susceptibility limit of 4.0 mg/L as was proposed by EUCAST.
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These in vitro data, however, do not necessarily predict in vivo efficacy of linezolid. Moreover, according to EUCAST, nonspecies-related breakpoints have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species. They are to be used only for species that have not been given a species-specific breakpoint. Regrettably, the EUCAST document does not explicitly state whether these breakpoints also apply to Fusobacterium spp. or not, although for Gram-negative anaerobes it is stated that susceptibility testing is not recommended as Gram-negative anaerobes are a poor target for therapy with linezolid. Yet, previous data together with our recent results indicate that this statement may not be fully correct. In view of European breakpoint harmonization efforts this issue should be further discussed. Furthermore, clinical trials on the impact of linezolid on severe anaerobic infections (e.g. soft tissue infections, peritonsillar abscess, pleuropulmonary infections) caused by Fusobacterium as well as possible side effects, i.e. on normal enteric or vaginal flora composition, are needed.
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